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Abstract In the present study, the validity of using a cocktail
screening method in combination with a chemometrical data
mining approach to evaluate metabolic activity and diversity
of drug-metabolizing bacterial Cytochrome P450 (CYP) BM3
mutants was investigated. In addition, the concept of utilizing
an in-house-developed library of CYP BM3 mutants as a
unique biocatalytic synthetic tool to support medicinal chem-
istry was evaluated. Metabolic efficiency of the mutant library
towards a selection of CYP model substrates, being amitrip-
tyline (AMI), buspirone (BUS), coumarine (COU), dextrome-
thorphan (DEX), diclofenac (DIC) and norethisterone (NET),
was investigated. First, metabolic activity of a selection of
CYP BM3 mutants was screened against AMI and BUS.
Subsequently, for a single CYP BM3 mutant, the effect of
co-administration of multiple drugs on the metabolic activity
and diversity towards AMI and BUS was investigated. Final-
ly, a cocktail of AMI, BUS, COU, DEX, DIC and NET was
screened against the whole in-house CYP BM3 library. Dif-
ferent validated quantitative and qualitative (U)HPLC-MS/
MS-based analytical methods were applied to screen for sub-
strate depletion and targeted product formation, followed by a
more in-depth screen for metabolic diversi ty. A
chemometrical approach was used to mine all data to search
for unique metabolic properties of the mutants and allow clas-
sification of the mutants. The latter would open the possibility
of obtaining a more in-depth mechanistic understanding of the
metabolites. The presented method is the first MS-based
method to screen CYP BM3 mutant libraries for diversity in
combination with a chemometrical approach to interpret re-
sults and visualize differences between the tested mutants.
Keywords Cytochrome P450 BM3 . Cocktail screening
approach . Chemometrics . Biocatalysis . LC-MS(/MS)
Introduction
Cytochrome P450 monooxygenases (CYPs) play an essential
role in metabolism of a wide range of xenobiotics and are
involved in biosynthesis of prostaglandins and steroid hor-
mones. CYPs catalyze hydroxylation, epoxidation, reduction
and other oxidative reactions on substrates that range from
alkanes to complex endogenous molecules such as drugs, ste-
roids and fatty acids [1]. The many reactions that CYPs can
catalyze make these enzymes highly versatile and very inter-
esting as tools to generate rather diverse and unique medicinal
compound libraries not always accessible via classical syn-
thetic routes. Moreover, in many cases these compounds show
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improved physico-chemical properties which is of crucial im-
portance during development of drug dosage forms. Metabo-
lites produced by CYPs are well known to display important
pharmacological activities or may be responsible for the tox-
icity or other unwanted side effects of xenobiotics [2, 3]. Sys-
tems enabling facile biosynthesis of sufficient quantities of
metabolites for structural elucidation and pharmacological
and toxicological evaluation are therefore highly desirable.
In addition, for drug discovery purposes metabolites are very
interesting during lead optimization as they may display im-
proved properties, such as target selectivity or even solubility
without significant loss of the pharmacological properties
compared to the parent drug itself [4].
The ideal biocatalyst possesses high turnover rates, is very
stable, can easily be expressed at high levels, and can function
under extreme conditions of temperature, pH, buffer system or
solvent. Although mammalian CYPs are capable of metabo-
lizing a wide array of substrates, they require additional redox
partners, display relatively low activities, give low expression
yields and have poor stability which makes them less suitable
for biocatalytic purposes [5]. The fatty acid-metabolizing
CYP BM3 from Bacillus megaterium is a very interesting
candidate because it is a natural fusion between a heme do-
main responsible for substrate oxidation and a diflavin reduc-
tase domain responsible for electron transport [6]. CYP BM3
possesses the highest activity ever measured and is a highly
stable enzyme [7]. These properties, in combination with
availability of crystal structures and large-scale expression
and purification protocols, make CYP BM3 a highly suitable
candidate for biocatalytic applications. Various protein engi-
neering techniques have already been successfully employed
to generate CYP BM3 mutants with increased activities and
altered regio- and stereoselectivities [8].
An important step during development of novel CYP BM3
mutants for biocatalytic purposes is selection of mutants that
display the desired changes. Therefore, mutant libraries which
have been created using different protein engineering tech-
niques need to be screened to select mutants with improved
characteristics. In order to improve throughput for screening
of CYP BM3 mutant libraries for different substrates, it may
be useful to screen the different substrates in a cocktail format.
Such an approach is already being used to study inhibitory
effects of drugs and new chemical entities (NCE) on human
CYP activities using a mixture of CYP-specific substrates in a
single human microsomal incubation in combination with tan-
dem mass spectrometry. These cocktail approaches have been
shown to be less time-consuming, less labour-intensive, more
cost-effective and thereby very powerful tools to study drug-
drug interactions due to CYP inhibition [9–13].
The aim of the present study was to investigate if a cocktail
approach could be used to screen CYP BM3 libraries for met-
abolic activity and diversity. Furthermore, it was of interest to
know if such an approach could be used in combination with
different chemometric tools in order to identify metabolites
without prior knowledge of their structure and identity. Firstly,
metabolic activity of a selection of well-characterized BM3
mutants from an in-house library was screened against two
drugs for which also metabolic profiles were determined. Sec-
ondly, for a single BM3 mutant, the effect of co-
administration of multiple drugs on the metabolic activity
and diversity was investigated. Based on these experiments,
a cocktail of drugs was selected against which the whole in-
house CYP BM3 mutant l ibrary was screened. A
chemometrical approach was subsequently used to analyse
the data generated by the qualitative HPLC-MS/MS-based
screening in order to determine if metabolites without prior
knowledge of their structure and identity could be detected. It
was demonstrated that a cocktail approach can be utilized to
screen CYP BM3 libraries for metabolic activity and diversity
and that a chemometrical approach is beneficial in order to
visualize and analyse the results generated during the library
screen.
Materials and methods
Chemicals
5-Hydroxybuspirone and 16β-hydroxy-17-epi-norethisterone
were purchased from Toronto Research Chemicals (Toronto,
Ontario, Canada). All other chemicals were of analytical grade
and were purchased from Sigma Aldrich (Zwijndrecht,
The Netherlands) unless stated otherwise.
Enzymes and plasmids
A total of 83 CYP BM3 mutants were used. Detailed infor-
mation about mutations present in the different mutants is
tabulated in the Electronic Supplementary Material (ESM),
Table S1. For 44 of the CYP BM3 mutants, construction has
been described previously [14–20]. In total, 39 novel mutants
were made by site-directed mutagenesis using the appropriate
oligonucleotides (see ESM, Table S1). In general, mutations
were introduced in the various templates in the pBluescript II
KS(+) vector using the QuickChange Site-Directed Mutagen-
esis Kit (Stratagene). Forward primers that were used are men-
tioned in the ESM, Table S2. Reverse primers were exactly
complementary to the forward primers. After mutagenesis,
the presence of the desired mutations was confirmed by
DNA sequencing (Service XS, Leiden, The Netherlands).
Genes of the novel site-directed mutants were cloned from
the pBluescript II KS(+) system, where they reside be-
tween the BamHI/EcoRI restriction sites, into the
pET28a+ vector.
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Expression of CYP BM3 mutants
His-tagged pET28a+ constructs of wild-type (WT) CYP BM3
and all mutants were transformed in Escherichia coli BL21
(DE3) cells using standard procedures. For expression,
600mLTerrific Broth (TB) [21] medium (24 g/Lyeast extract,
12 g/L tryptone, 2 g/L peptone, 20mL/L glycerol) with 30 μg/
mL kanamycin was inoculated with 15 mL of an overnight
culture. Cells were grown at 175 rpm and 37 °C until OD600
reached 0.6. Protein expression was induced by addition of
0.6 mM isopropyl-β-D-thiogalactopyrasonide (IPTG). Tem-
perature was lowered to 20 °C and 0.5 mM of the heme pre-
cursor δ-aminolevulinic acid was added. Expression was
allowed to proceed for 18 h. Cells were harvested by centri-
fugation (4600×g, 4 °C, 25 min), and the pellet was resus-
pended in 20 mL KPi-glycerol buffer (100 mM potassium
phosphate (KPi) pH=7.4, 10 % glycerol, 0.5 mM EDTA
and 0.25 mM dithiothreitol). Cells were disrupted using an
EmulsiFlex-C3 (Avestin Inc., Ottawa, Ontario, Canada;
1000 psi, 3 repeats), and the cytosolic fraction was separated
from the membrane fraction by ultracentrifugation of the ly-
sate (120,000×g, 4 °C, 60 min). CYP concentrations were
determined using the carbon monoxide (CO) difference spec-
trum assay as described by Omura et al. [22].
CYP BM3-mediated metabolism of the drugs
amitriptyline and buspirone
Metabolic incubations for the drugs amitriptyline (AMI) and
buspirone (BUS) were performed in 100 mM potassium phos-
phate (KPi) buffer at pH 7.4 with the cytosolic fraction con-
taining 100 nM of BM3 mutant at a 40-μM substrate concen-
tration. Final volume of the incubations was 250 μL, and the
final DMSO concentration was always 5 %. Reactions were
initiated by the addition of 50 μL of NADPH-regenerating
system (NRS; final concentrations: 50 μM NADPH,
2.5 mM glucose-6-phosphate and 0.5 U/mL glucose-6-
phosphate dehydrogenase). Reactions were allowed to pro-
ceed for 60 min at 24 °C and were terminated by addition of
250 μL ice-cold acetonitrile (ACN). Samples were subse-
quently centrifuged to remove precipitated protein (14,
000 rpm for 15 min) and supernatants were analysed by LC-
MS/MS.
Electrospray ionization LC-MS/MS analyses in the posi-
tive ion mode were carried out at the Division of Molecular
Toxicology at the Vrije Universiteit in Amsterdam,
The Netherlands. Metabolites and parent compounds were
analyzed by reversed phase chromatography using a Synergi
MAX-RP column (Synergi, 4 μm, 150 × 4.6 mm i.d.;
Phenomenex, Amstelveen, The Netherlands) at a flow rate
of 0.3 mL/min. The gradient was composed of solvent A
(0.1 % v/v formic acid in water) and solvent B (0.1 % v/v
formic acid in ACN). For the various substrates, different
gradient programs were used. For identification of substrates
and metabolites, a Finnigan LCQ Deca mass spectrometer
(ThermoQuest-Finnigan) was used operating in the positive
ion electrospray mode. N2 was used as a sheath gas (60 psi)
and auxiliary gas (10 psi); the needle voltage was 5000 Vand
the heated capillary was at 150 °C. LC-MS/MS data of the
substrates and bio transformation products were processed
with Xcalibur/Qual Browser v 1.2 (ThermoQuest-Finnigan).
Standard curves of the substrates were linear between 0.1 and
100 μM.
Effects of co-administration of multiple drugs
To investigate effects of co-administration of multiple drugs,
incubations were performed with CYP BM3 mutant MT72
(M11 V87F) using the marketed drugs AMI, BUS, coumarine
(COU), clozapine (CLZ), dextromethorphan (DEX) and
norethisterone (NET) in different combinations. All incuba-
tions had a final volume of 250 μL and consisted of KPi
containing 250 nM of the cytosolic fraction of MT72 while
the final DMSO concentrations were always of 5 %. The
concentration of each individual drug was set at 100 μM.
Reactions were initiated by addition of 50 μL NRS and were
allowed to proceed for 60 min at 24 °C after which 750 μL
ice-cold ACN was added. Samples were subsequently centri-
fuged to remove precipitated protein (14,000 rpm for 15 min)
and supernatants were analysed by LC-MS.
LC-ESI-MS analyses were carried out at the Division of
Molecular Toxicology at the Vrije Universiteit in Amsterdam,
The Netherlands. Extracts were separated by reversed phase
chromatography using a C18 column (Luna C18(2), 5 μm,
4 . 6 × 150 mm i . d . ; Ph enomenex , Ams t e l v e en ,
The Netherlands) at a flow rate of 0.5 mL/min and a temper-
ature of 25 °C. The gradient was composed of solvent A
(0.1 % formic acid in water) and solvent B (0.1 % formic acid
in ACN). The samples were analyzed on an Agilent 1200
Series Rapid resolution LC equipped with a Time-Of-Flight
(TOF) Agilent 6230mass spectrometer (Agilent technologies,
Waldbronn, Germany). The electrospray interface was operat-
ed at a capillary voltage of 3500 V with N2 as drying gas
(12 L/min) and nebulizer gas (pressure 60 psig). The gas tem-
perature was 350 °C during operation. The TOF was used in
the positive ion mode, and data was acquired using the Mass
Hunter workstation software (version B.06.00). Standard
curves of the substrates were linear between 0.1 and 100 μM.
Screening of the CYP BM3 library using a cocktail
approach
The degree of metabolism of six marketed drugs by the total
CYP BM3 library was investigated using a cocktail approach.
The six drugs used for this experiment were AMI, BUS, COU,
DEX, diclofenac (DIC) and NET. The concentration of the six
Application of a cocktail approach to screen cytochrome P450 BM3 1427
marketed drugs was set at 100 μM, the final DMSO concen-
tration in the incubation was set at 5 % and all CYP BM3
mutants were incubated at a 250-nM enzyme concentration.
Reactions were initiated by addition of 50 μL NRS and were
allowed to proceed for 60 min at 24 °C. To terminate reac-
tions, 250 μL of ice-cold ACN containing 50 μM minaprine
was added after which samples were subsequently centrifuged
to remove precipitated protein (14,000 rpm for 15 min). Each
sample was analysed by UPLC-MS/MS while a selection of
samples was also analysed by LC-MS.
UPLC-MS/MS analyses were carried out at QPS Nether-
lands B.V. in Groningen, The Netherlands. For UPLC-MS/
MS, an AB SCIEX API 4000™ tandem MS System (AB
SCIEX, Framingham,MA, USA) hyphenated with an Agilent
1290 Infinity Binary LC System (Agilent technologies,
Waldbronn, Germany) was used. Electrospray ionization and
a Multiple Reaction Monitoring (MRM) scan mode with a
dwell time of 10 ms/s (see for more details the ESM,
Table S3) was used. Instrument conditions were as follows:
collision gas (CUR) 35, curtain gas (CAD), GS1 50, GS2 50,
ion spray voltage 5500 and source temperature 550 °C. For
sample pretreatment, 10 μL of supernatant from the incuba-
tions was mixed with 2000 μL mobile phase (90:10, A/B) to
which 50 nM MIN was added. From this pretreated sample,
5 μL was injected for analysis. Separation was achieved with
an Acquity UPLC BEH column (1.7 μm particles, 2.1 ×
50 mm; Waters, Milford, USA) at a flow rate of 0.3 mL/min
and a temperature of 40 °C. The data were processed with
commercial available Analyst 1.4.1 (AB SCIEX) software.
Standard calibration curves of all substrates and metabolites
were linear between 0.1 and 100 μM.
LC-ESI-MS/MS analyses were carried out at the
BioAnalytical Chemistry at the Vrije Universiteit in Amster-
dam, The Netherlands. A Shimadzu (‘s Hertogenbosch,
The Netherlands) ion-trap time-of-flight (IT-TOF) hybrid
mass spectrometer equipped with a Shimadzu LC system
(SIL-20 AC autoinjector, two LC-20AD pumps, CT-20AC
column oven, SPD-AD UV/VIS detector and a CBM-20A
controller) was used. The needle voltage was set to 4.5 kV,
and the source heating block and the curved desolvation line
were kept at 200 °C. A drying gas pressure of 62 kPa and a
nebulizing gas (N2) flow rate of 1.5 L/min assisted the ioniza-
tion. Full spectra were obtained in the positive ion mode be-
tween m/z 140 and 450. MS2 spectra were obtained in a data-
dependent mode between m/z 100 and 450 with an ion accu-
mulation time of 10 ms, a precursor width of 3 Da and a
collision energy of 75 %. For sample pretreatment, 20 μL of
supernatant from the incubations was mixed with 80 μL of
50 % ACN. From this pretreated sample, 12 μL was injected
for analysis. Chromatography was performed on a Synergi
MAX-RP column (Synergi, 4 μm, 150 × 4.6 mm i.d.;
Phenomenex, Amstelveen, The Netherlands) at a flow rate
of 0.4 mL/min and a temperature of 25 °C. The gradient was
composed of solvent A (0.1 % formic acid in water) and sol-
vent B (0.1 % formic acid in ACN). The data were processed
with LCMS solution Version 3.60.361 (Shimadzu).
Chemometric analyses
Raw data (.cdf files) resulting from LC-MS analyses of the
CYP BM3 library screening using the cocktail approach
(BM3-Cocktail data) were read into the R data analysis envi-
ronment (R, 2.15, http://cran.r-project.org/) using the R ncdf
package (version 1.6.6) and binned according to a m/z range
of ±0.5 using the MassView package. TheMassView package
has been made in-house for binning mass data according to a
specifiedm/z range and uses the caMassClass package version
1.9 (ht tp: / /cran.rproject .org/src/contr ib/Archive/
caMassClass/). Data between 10 and 26.2 min were used for
further analysis. Alignment of spectra was carried out with
Parametric Time Warping (PTW) [23] using the R ptw pack-
age [24]. After zero padding (addition of 1000 zeros before
and after each chromatogram for eachm/z), PTW was execut-
ed twice using the mean chromatograms of the zero padded
data and the aligned data, respectively, as reference. Resulting
aligned data were converted in Matlab format using the R.
matlab library 1.6.1 [25]. The size of the resulting data was
84×310×9720 (samples × m/z × time-points). For peak de-
tection (for each nominalm/z), the method of Zhang et al. was
applied [26]. The method is based on wavelets (haar wavelet,
scale factor 60). Peaks (noise) below a value of 50,000 were
not taken into account. Before peak detection, the chromato-
grams for each m/z were smoothed using a wavelet smoother
(dog wavelet, Matlab cwtft function). Detected peaks with a
signal-to-noise ratio below 2 (mostly chemical noise) were
removed (noise calculated at the start- and endpoint of the
peak using the data before smoothing). Detected peaks were
integrated and stored in an array combinedwith associatedm/z
and time of peak maximum. During this procedure, correc-
tions were made for small residual misalignment of peaks
between the different samples (up to 3 s). To correct for sam-
ple processing variations and mass detector sensitivity chang-
es, the data were normalised to the total mass of the first
sample. Isotopes of substances were removed for m/z+1,
m/z+2, m/z+3 and m/z+4 with additional constraints on the
peak height ratios (roughly based on the natural ratios of 1H/D
and Cl35/Cl37). Small differences in retention time were
allowed (<15 s). Peaks related to substances present in the
eluent, solvent and incubation solution and peaks of the sub-
strates and the internal standard were removed using the peaks
present in the WT sample. The resulting data is expected to
comprise of the metabolites formed by enzymatic conversion
of the substrates.
Outlier analysis was executed using Robust PCA [27]. Im-
plementation in the Matlab-based LIBRA package was ap-
plied [28]. ROBPCA was applied using default settings. For
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retrieval of the contributing variables, the partial decomposi-
tion methodology of Alcale et al. [29] was implemented. For
determination of the number of latent variables, the estimate
factors function of the PLS toolbox was applied (PLS toolbox
Version 7.0, Eigenvector Research, Inc., Manson USA). The
principle of this function is that it selects those principal com-
ponents which appear to be stable during resampling of the
data. Clustering of data was obtained using hierarchical clus-
tering [30]. Built-in Matlab procedures were used (Matlab
version R2012b, Matlab, The MathWorks Inc., Natick, Mas-
sachusetts, USA). Besides these procedures and functions,
several in-house functions were constructed to easily visualize
subsets of the data. Functions were constructed to visualize
m/z traces (chromatograms) for one specific m/z value for all
samples and to visualize the identified peaks for a specificm/z
and retention time combination in all samples.
Results and discussion
Selection of the CYP BM3 mutants
The aim of the present study is to investigate if a cocktail
approach can be used to screen CYP BM3 libraries for meta-
bolic activity and diversity. It was therefore decided to employ
a CYP BM3 library consisting of mutants with as much struc-
tural diversity as possible by selecting mutants with mutations
that preferably were introduced throughout the whole protein
structure. In addition, CYP expression levels of the selected
mutants needed to be suitable to allow large-scale enzyme
expression. Mutants that were used in the current study were
a combination of 44 mutants that have been described previ-
ously [14–20] complemented with 39 novel CYP BM3 mu-
tants (see ESM, Table S1).
The set of 44 previously described mutants include M01,
M02,M05 andM11whichwere constructed by a combination
of three site-directed mutations (R47L, F87Vand L188Q) and
subsequent rounds of random mutagenesis by error-prone
PCR [31]. The 40 other mutants have all been based upon
these four templates. This set of mutants has previously been
tested against a range of substrates, including marketed drugs
[14, 16, 32, 33], steroids [15, 18, 20], ionones [19], kinase
inhibitors [34], alkoxyresorufins [15, 17] and endocrine
disrupting chemicals [17, 35]. They metabolized these sub-
strates with varying catalytic activities while also displaying
significant differences in the metabolic profiles generated. The
39 mutants that have not been described previously were all
created in-house by site-directed mutagenesis using the appro-
priate mutant templates (see ESM, Table S2). Mutations have
been introduced at different positions throughout the protein
in order to address, amongst others, effects upon regio- and
stereo-selectivity (residues 72, 74, 75, 81, 82, 86, 87, 264,
328, 436, 437 and 440), organic solvent tolerability (residues
235, 471, 494 and 1024, see also [36]) and protein stability
(residues 53, 176, 208 and 359). In-depth discussion of these
properties is not a subject in this manuscript and will not be
addressed.
Expression levels and stability ofWTCYP BM3 and all 83
mutants were determined by measuring intensity of the char-
acteristic Soret band at 450 nm upon reduction by dithionite
and addition of CO. All cytosolic BM3 fractions were found
to contain stable and active CYP protein. Although expression
yields varied amongst the different mutants (data not shown),
at least 50 nmols of active CYP protein was expressed per
600 mL of TB culture for each mutant and the WT enzyme.
Cytosolic fractions were used to prepare 5 μM stock solutions
in KPi-glycerol buffer for the WT enzyme and all mutants.
Characterization of the CYP BM3 library-using
amitriptyline and buspirone
In order to investigate the applicability of a cocktail approach
to screen CYP BM3 libraries for metabolic activity and diver-
sity, information is needed about activity of the mutants to-
wards single substrates that are present in the cocktail. Since
AMI and BUS have previously been successfully used to
probe differences between CYP BM3 mutants, showing sig-
nificant differences in metabolite profiles [16], it was decided
to screen theWTenzyme and a selection of 43mutants against
both drugs. Figure 1a, b shows the diversity of the 44 tested
enzymes towards AMI and BUS, respectively. As can be seen,
both drugs are metabolized by almost all CYP BM3 mutants
with varying activities into different metabolites.
For AMI (see Fig. 1a), the major product in all cases was
nortriptyline (NOR; MA4) which is consistent with previous
results [16]. Significant amounts ofMA2 are only formed by a
small number of mutants (MT35, MT59, MT66, MT67,
MT68, MT72, MT90 and MT91). It is interesting to observe
that all mutants that form MA2 contain a mutation at amino
acid residue 87, residue 437 or mutations at both of these
residues. MA1, MA3 and MA5 were formed by almost all
mutants although at varying levels. The WT enzyme did not
display any activity while MT76 only formed a very small
amount of MA4. Identification of the metabolites of AMI is
discussed in more detail in the ESM.
For BUS (see Fig. 1b), it was observed that significant
differences existed between metabolite distribution profiles
generated by the tested mutants. The WT enzyme, MT65
and MT76 did not display any activity towards BUS. MB4
(5-OH-BUS) was produced by all other mutants, although this
was not the major metabolite in every incubation analysed.
MB1 was not formed by MT64, MT65, MT66, MT70,
MT71 and MT76, having in common that they contain a mu-
tation at the 87 position (V87Q, V87E, V87G, V87K, V87M
and V87W, respectively). When compared to their template
M11, for MT70 and MT71, it appears that the mutation at
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position 87 resulted in a very large decrease of metabolic
activity confirming that this position is crucial for efficient
biotransformation of substrates [15]. MB2 was only formed
by a selection of mutants (M01, M02, MT31, MT38, MT41,
MT43, MT44, MT59, MT104 and MT107). The majority of
the mutant library is derived from M11 (M11 + 28 M11-
mutants; 66 %) while besides the WT enzyme, M02 and
M05 the rest of the library is derived from M01 (M01 + 12
M01-mutants: 27 %). It is interesting to note that of the ten
mutants that formMB2, only two are derived fromM11 while
the majority is derived from M01. These results suggest that
the additional mutations in M11 compared to M01 and M02
(F81I, E143G, Y198C and H285Y) have an effect on the
metabolism of BUS which is probably mainly caused by
mutation of the active-site residue phenylalanine at position
81 into isoleucine. Significant amounts of MB3 were only
produced by M01, M02, MT59, MT66 and MT80 while
MB4 and MB5 were formed by almost all mutants although
at varying levels. Identification of the metabolites of BUS is
discussed in more detail in the ESM.
From all these data, it was again proven that the 87 position
is crucial, and that significant differences in activity and me-
tabolite profiles could be obtained with the mutant library.
Validation of the cocktail screening approach
Having an established CYP BM3 mutant library, the next step
in development of the cocktail screening was to investigate
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Fig. 1 Product profile and
activity of CYP BM3 engineered
variants towards amitriptyline (A)
and buspirone (B). Activities
were determined by calculating
the substrate depletion using the
average peak area of the parent at
60 min and at time zero. Values
represent the mean of two
independent experiments with
less than 10 % error. Product
selectivity in % was calculated
from the extracted ion
chromatograms and is represented
by different shades in each bar
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effects of co-administration of multiple drug substrates. Sub-
strate mixes of various compositions were made, and effects
of co-administration of multiple drugs on the metabolic activ-
ity and metabolic product profile of AMI and/or BUS by a
single CYP BM3 mutant were investigated. The CYP BM3
mutant chosen for this experiment was MT72 since it
displayed good activity towards both AMI and BUS during
the previous single substrate screening experiment (see
Fig. 1a, b). Besides AMI and BUS, the marketed drugs cloza-
pine (CLZ), coumarin (COU), dextromethorphan (DEX) and
norethisterone (NET) were selected for this experiment based
on previous studies [20, 31, 32] (see Fig. 2 for chemical struc-
tures). Concentrations of the substrates were set at 100 μM
which is higher than the concentrations used during the single
substrate screening experiment (40 μM). In the latter experi-
ment, a number of mutants displayed very high conversions
(above 80 %) towards both AMI and BUS. It was therefore
decided to increase all substrate concentrations to 100 μM.
As can be seen from Table 1, substrate depletion was ob-
served for all drugs screened in all incubations. When looking
at the metabolic activity of MT72 towards AMI, it can be seen
that the amount of AMI depletion varies between 34 and 64%
while the average AMI depletion in these incubations is
46.4 % with a standard deviation of 8.3 % (overall precision
(CV) of 18 %). This amount of substrate depletion corre-
sponds very well with the results from the single substrate
screening experiment during which a depletion of 48.6 %
was measured for MT72. There is no clear trend to observe
in the effect of co-administration of the marketed drugs, as all
drugs tested did not significantly induce or inhibit the metab-
olism of AMI and the number of drugs co-administered had
no effect on the metabolic activity. Furthermore, it can be seen
from Fig. 3a that the metabolite distribution is not affected by
co-administration of multiple drugs. For AMI, the expected
metabolites MA1-MA5 (based on the single substrate screen-
ing experiment) were formed while also the metabolic profile
generated was similar as before (see Fig. 1a).
Considering the metabolic activity of MT72 towards BUS,
it can be seen that the amount of BUS depletion varies be-
tween 53 and 77 % while the average BUS depletion in these
incubations is 61.7 % with a standard deviation of 7.9 % (CV
of 13%). These findings correspond very well with the results
from the single substrate screening in which a depletion of
60.2 % was measured. No significant alteration of the metab-
olite distribution occurs as result of the co-administration (see
Fig. 3b). For BUS, the expected metabolites MB1, MB3,
MB4, MB5 and MB6 (based on the single substrate screening
experiment) were formedwhile also the metabolic profile gen-
erated was similar as before (see Fig. 1b).
For CLZ, DEX and NET, metabolic activity (see Table 1)
and diversity (data not shown) were not affected by co-
administration of multiple drugs.Metabolic activity was much
lower than the activity observed for AMI and BUS (substrate
depletion ranging between 3 and 9 %). CLZ was metabolized
into two metabolites by MT72 which were identified as being
clozapine N-oxide and N-desmethylclozapine, respectively.
DEX was metabolized into a total of four products. Two prod-
ucts were a result of hydroxylation (MD3 andMD4) while the
two other products were a result of demethylation (MD5 and
MD6). NET was metabolized into one monohydroxylated
product, MN1. Identification of the metabolites of CLZ,
DEX and NET is discussed in more detail in the ESM.
For COU, substrate depletion was observed in all incuba-
tions. However, in none of the incubations, COU-related me-
tabolites were detected. Besides the possibility that the ab-
sence of metabolites is caused by the simple fact that no bio-
transformation occurred, MS signals of metabolites might
have been too low for detection caused by lack of optimal
ionization conditions since MS signals of COU itself were
also much lower (at least ten times) than the signals of the
other drugs. Another possible explanation for the absence of
COU-related metabolites is that COU might be metabolized
into coumarin 3,4-epoxide (CE) which is a reactive interme-
diate that can react with proteins present in the incubation and
could therefore not be detected. Subsequently, CE can be fur-
ther metabolized into o-hydroxyphenylacetaldehyde (o-HPA).
This metabolite has also not been detected in any of the
incubations.
In conclusion, no inhibition of the biocatalytic activity of
the CYP BM3 mutant MT72 for the applied substrates was
observed. Neither did the molecular profiles of the metabolites
change, indicating that the cocktail incubation is a valid ap-
proach for the generation of unique compound libraries and
for the screening of unique biocatalytic properties of BM3
mutants.
Screening of the CYP BM3 library using a cocktail
approach
The next step of our study was to screen the complete CYP
BM3 library encompassing the 83 mutants and the WT en-
zyme in a cocktail approach to investigate if such an approach
can be used to rapidly classify mutant CYP BM3 libraries for
both metabolic activity and diversity. The substrates that were
selected for the cocktail screening experiment were AMI,
BUS, COU, DEX, diclofenac (DIC) and NET. Besides one
case report where a life-threatening dextromethorphan intox-
ication was associated with interaction with amitriptyline in a
poor CYP2D6 metabolizer [37], no reports have been pub-
lished about the interactions of any two or more of these
drugs. Based on this information and the co-administration
experiment described above, occurrence of drug interactions
is not expected to have an impact. In order to rapidly assess
bioactivity of the mutants, for each substrate, one of the pre-
viously described biotransformations was monitored. Based
upon the single substrate screening experiment, NOR (MA4)
Application of a cocktail approach to screen cytochrome P450 BM3 1431
Fig. 2 Structures of the marketed
drug substrates that were used in
this study. The molecular weight
(MW) is indicated for each
substrate
Table 1 Effect of co-
administration of multiple drugs
on metabolic activity of MT72
Sample AMI (%)a BUS (%)a CLZ (%)a COU (%)a DEX (%)a NET (%)a
1 49.3 ± 0.7 np np np np np
2 np 60.3 ± 1.3 np np np np
3 np np 4.0 ± 2.7 np np np
4 np np np 13.1 ± 3.08 np np
5 np np np np 7.3 ± 0.7 np
6 np np np np np 1.7 ± 1.0
7 37.7 ± 2.2 56.6 ± 2.8 np np np np
8 56.5 ± 6.0 np 8.5 ± 2.4 np np np
9 51.6 ± 0.6 np np 8.1 ± 1.9 np np
10 35.5 ± 0.5 np np np 5.0 ± 0.2 np
11 64.0 ± 2.5 np np np np 1.6 ± 0.12
12 np 69.5 ± 12.1 6.9 ± 3.9 np np np
13 np 76.2 ± 6.2 np 11.3 ± 1.7 np np
14 np 61.1 ± 1.7 np np 7.1 ± 0.5 np
15 np 60.2 ± 0.8 np np np 4.2 ± 0.5
16 34.6 ± 2.1 54.0 ± 2.1 2.0 ± 1.1 np np np
17 42.0 ± 3.6 61.4 ± 4.3 np 8.1 ± 1.6 np np
18 37.3 ± 1.0 55.8 ± 1.4 np np 2.2 ± 0.2 np
19 43.9 ± 4.5 60.2 ± 5.4 np np np 1.8 ± 1.0
20 41.2 ± 3.4 60.5 ± 4.6 8.4 ± 1.2 8.9 ± 0.5 np np
21 43.5 ± 8.3 63.4 ± 11.9 8.1 ± 1.3 np 6.7 ± 0.4 np
22 51.8 ± 14.4 68.8 ± 18.1 9.6 ± 3.1 np np 3.2 ± 2.9
23 47.8 ± 10.0 69.0 ± 13.9 np 7.4 ± 0.7 6.2 ± 0.5 np
24 51.6 ± 12.4 69.0 ± 15.6 np 3.2 ± 3.9 np 1.7 ± 0.9
25 46.5 ± 2.9 60.8 ± 4.3 np np 6.5 ± 1.8 3.2 ± 0.9
26 35.9 ± 0.3 53.3 ± 0.6 4.2 ± 0.2 4.6 ± 0.2 3.7 ± 1.6 np
27 44.4 ± 3.5 58.3 ± 2.9 9.3 ± 1.7 9.2 ± 3.5 np 3.4 ± 2.6
28 45.5 ± 2.1 60.1 ± 2.5 6.0 ± 0.5 np 4.0 ± 2.4 2.7 ± 1.4
29 43.5 ± 1.5 56.4 ± 0.7 np 9.2 ± 2.0 6.2 ± 3.7 3.4 ± 2.8
30 51.6 ± 3.8 61.3 ± 3.8 15.0 ± 2.5 12.6 ± 6.7 8.6 ± 2.6 6.0 ± 4.7
Average 46.4 ± 8.3 61.7 ± 7.9 7.5 ± 3.8 8.7 ± 3.6 5.8 ± 2.2 3.0 ± 2.0
a The substrate depletion is calculated by using the average peak area of the parent at 60 min and at time zero.
Values are expressed in percentages of the average peak area of the parent at time zero. Measurements were
performed in duplicate. ‘np’ indicates that the substrate was not present in the corresponding incubation
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and 5-OH-BUS (MB4) were selected for AMI and BUS, re-
spectively. 7-OH-COU was selected as probe metabolite for
COU. The demethylated products dextrorphan (MD5) and
MM (MD6) were selected as probe metabolites for DEX
whereas 4-OH-DIC was selected for DIC. For NET, 16β-
hydroxy-17-epi-norethisterone was used as a probe metabo-
lite. Standard calibration curves of all substrates and metabo-
lites were obtained, and the limit of detection was below
0.1 μM in all cases. The results of the cocktail screening
experiment are shown in Table 2.
It can be seen that significant differences exist between
metabolic activities of the different mutants towards the six
drugs. The averaged standard deviation of the substrate deple-
tions calculated were below 15 % for all substrates (see also
ESM, Table S4). Averaged standard deviation of the metabo-
lite concentrations determined were 3.0, 0.3, 1.0 and 0.4 μM
for NOR, 5-OH-BUS, MM and OH-DIC, respectively. For
AMI, detection of the metabolite NOR corresponded well
with the amount of substrate depletion observed. This is in
agreement with the previous finding that NOR was the major
metabolite during the single substrate screening experiment.
For BUS, the substrate depletion determined was in most
cases significantly higher than the amount of 5-OH-BUS de-
tected. This indicates that more metabolites are formed which
agrees with the previous results of the single substrate screen-
ing experiments. For COU, significant amounts of substrate
depletion were observed with MT24 being the most active
mutant. However, no formation of 7-OH-COU was detected.
For DEX, formation of the N-demethylated product MM was
detected while formation of the O-demethylated product
dextrorphan was not detected. When comparing the amount
of substrate depletion with the concentration of metabolite
detected, it can be seen that in many cases the concentration
of MM formed is higher than the amount of DEX which has
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Fig. 3 Effect of co-
administration of multiple drugs
on the metabolic profile of the
drugs amitriptyline (A) and
buspirone (B) generated by
MT72. The sample numbers
correspond to the incubations
represented in Table 1
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been consumed. In addition, for several mutants, a negative
amount of substrate depletion was observed. A possible ex-
planation for these effects is, again, that factors present (in-
cluding formed metabolites) in the incubation mixture may
influence the MS signals of DEX and MM. For DIC, forma-
tion of 4-OH-DICwas detected, and inmost cases, the amount
of substrate depletion observed was higher than the concen-
tration of 4-OH-DIC detected. This could indicate that other
products are formed and agrees with the previous finding that
DIC can be converted by CYP BM3 mutants into reactive
metabolites [38], although in the respective study the amount
of GSH-conjugates formed by most mutants did not account
for more than 10 % of the total amount of metabolites pro-
duced. For NET, significant differences in the amounts of
substrate depletion were determined for the tested mutants.
However, formation of 16β-hydroxy-17-epi-norethisterone
was not detected in any of the incubations. For a number of
mutants, a negative amount of substrate depletion was
observed.
Selected incubations were qualitatively analyzed by LC-
MS/MS on a Shimadzu IT-TOF in order to provide accurate
mass information on the substrates, metabolites and their frag-
ment ions and thereby get more information about the meta-
bolic profiles generated by the different mutants for the six
drugs tested. For each mutant, one sample of the incubation at
60 min was analyzed while for a selection of mutants also an
incubation at time zero was analyzed.
Interpretation of the cocktail screening data
In order to scan the data in depth for known, but also unknown
metabolites, several questions can be asked and several strat-
egies can be followed. Regarding the questions, one can try,
e.g. to: (1) look for all metabolites that are produced, (2) look
for mutants that uniquely produce certain metabolites, (3) look
for the most active mutants, (4) relate groups of enzyme mu-
tations to certain metabolic processes, or (5) look for muta-
tions whichmore efficiently produce certain metabolites.With
respect to the strategies, one can (a) manually scan the data for
all theoretical possible metabolic conversions (and combina-
tions of conversions) for all substrates and (b) use certain
procedures and techniques which are more specifically
targeted at the different questions. The former strategy is a
rather laborious strategy, especially if multiple substrates need
to be investigated in combination with large numbers of mu-
tant enzymes. In this case, an untargeted approach provides a
better alternative. There are several simple data visualization
and analytical techniques available to facilitate screening and
investigation of data resulting from experiments in view of the
various afore mentioned questions. First of all, raw LC-MS
data files need to be pre-processed. Katajamaa and Orešič [39]
and Draper et al. [40] describe the possible steps in the data
(pre)processing (processing pipeline). In this work, we have
followed a slightly different order. Firstly, data were aligned
using PTW, followed by a peak detection procedure, as de-
scribed in the ‘Materials and Methods’ section. The result of
the application of such a processing pipeline is a reduced data
set containing only peaks (including peak area or height, po-
sition in time and m/z dimension) of substances which could
be of possible interest.
One of the most basic methods to obtain a visual overview
of such multidimensional data is PCA, which can be com-
bined with information on the most important variables
(peaks) using a biplot [41]. PCA focusses on the variation in
data. Frequently, this variation is due to metabolites that are
produced in high quantities by most enzymes (cf. questions 1
and 3). If one wants to focus on those mutants that are specif-
ically producing one or a few metabolites (cf. question 2),
these cannot readily be identified using PCA and therefore
another approach needs to be applied. Robust PCA is a meth-
odology specifically constructed for identifying potential out-
liers in data sets. Selected mutant enzymes that produce spe-
cific metabolites differ from most other enzymes and thus can
be viewed as being outliers. Moreover, clustering techniques
can be applied to facilitate recognition of certain groupings in
the data being either the detected peaks or the types and sites
of mutations. For a comparison between the various chemo-
metric analyses and manual data analysis, we have also man-
ually screened all IT-TOF MS data files upon the presence of
CYP-related metabolites. For quantification of the parents and
metabolites, peak areas from the MS spectra were assumed to
yield similar MS responses, although it is realized that MS
signals generated by the different metabolites in most cases
are not similar to those generated by the parent compound.
However, as no UV data is available, quantification based
upon the MS signal is the only alternative in order to generate
metabolite profiles. Detailed results of the qualitative analysis
of the metabolism of AMI, BUS, DEX, DIC and NET can be
found in the ESM (Figures S1-S5).
The result of the application of PCA on pre-processed data
from which substrates and their isotopes are removed is visi-
ble in Fig. 4a. This is a so-called biplot in which samples are
presented together with (in this case a subset of) peaks mainly
responsible for the spread in the data. From right to left, there
is an increase in metabolic production. A zoomed-in version
of the samples on the right is visible in Fig. 4b. Clearly, the
samples can be identified that hardly or not display any sig-
nificant activity or metabolite formation for any of the drugs
tested.
The data describing the mutations present in the CYP BM3
library (with zeros and ones, the latter indicating that a certain
mutation is present in a mutant) can also be subjected to clus-
tering. Based on the so-called cityblock distance and using
average linkage hierarchical clustering, the data was clustered
in 6/8 clusters: 5/7 small clusters and one large cluster. If the
mutants in Fig. 4a are coloured according to this clustering,
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this results in Fig. 4c, d. This plot does not reveal much infor-
mation, apart from one striking feature: the mutants belonging
to the dark green cluster are located either on the right side of
the figure (MT21, MT22, MT87, MT88; MT0 is the WT; see
Fig. 4d), indicating that they do not produce anymetabolite, or
in the centre of the figure (MT16 and MT17). All these mu-
tants contain only one to four mutations. The latter two mu-
tants only contain the mutation A964V and G1049E,
respectively, indicating that these mutations could be impor-
tant for the production of metabolites.
In Fig. 4a, c, the mainmetabolites of the different substrates
can be tentatively identified on basis of the mass spectrometric
data. Several of the peaks in this plot are metabolites of AMI.
The peak at m/z 264@13.93 (and its isotope at m/z
265@13.93) is the major metabolite MA4 (NOR). The peak
at m/z 294@14.27 corresponds with MA3, while peak at m/z
Fig. 4 Biplot of the pre-processed data. The samples are identified with
the MT-number, the peaks indicated by lines and labelled with the
corresponding m/z and retention time. The small numbers indicate the
order of samples in the data set. 0 (84) indicates the WT. (A) The data
are coloured according to a hierarchical clustering (average linkage) of
the data based on 5 clusters. In order to prevent that too many peaks are
plotted a user definable threshold of mostly 10 % of the largest peak was
used; (B) zoomed-in version of the central right part of (A); (C) biplot of
the pre-processed data with colour coding according to the clustering of
the mutation patterns of the mutants (using hierarchical clustering,
average linkage) based on 6 clusters; (D) zoomed-in version of the
central right part of (c)
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250@13.78, corresponding withMA5, is also formed bymost
mutants. That they appear in this plot indicates that they ex-
plain the largest variation between the samples and that they
are probably present in a large number of samples in high
concentration. This is confirmed by Fig. 1a and ESM
Fig S1. By checking the mass trace of m/z 294, more metab-
olites can be identified (MA1 at 12.3 min and MA2 at
12.8 min; see ESM Fig S6). By checking the corresponding
mutants, it can be concluded that MA2 is formed mainly by
mutants containing a mutation at position 87, position 437 or
mutations at both of these positions which is in agreement
with the results from the single substrate screening
experiment.
The largest peak in Fig. 4a is the result of a DEXmetabolite
(see below for more details). When this DEX metabolite and
the AMI metabolite MA4 are removed from the data, three
metabolites of BUS appear in the biplot (data not shown). The
most prominent peak at m/z 402@12.39 corresponds to MB4
(5-OH-BUS) while the peaks at m/z 402@12.87 and at m/z
360@12.14 correspond to MB5 and MB6, respectively. If the
mass trace of m/z 402 is plotted (ESM Fig S7), five different
metabolites appear in different quantities. Almost all mutants
form MB4 (5-OH-BUS) while MB2 is only formed by a lim-
ited number of mutants. This is in agreement with the results
from the single substrate screening experiment. For formation
of MB2, again, the trend is observed that the majority of the
mutants that form significant amounts of this metabolite do
not contain the F81I mutations. The fact that mutant MT122,
which is a mutant of M01 where the F81I mutation was intro-
duced, does not form MB2 supports this hypothesis. In
Table 3, a comparison has been made between the results of
the screens for metabolic activity and diversity for a selection
of mutants towards AMI and BUS. It can be seen from Table 3
that differences exist between the results from the different
screenings. The substrate depletions calculated based on the
results of the qualitative analysis by IT-TOF are in almost all
cases (except for MT68-mediated conversion of BUS) lower
than the substrate depletion calculated from the quantitative
analysis by UPLC-MS/MS. This can be caused by the fact that
MS signals generated by the different metabolites are not sim-
ilar to those generated by the parent compound. The discrep-
ancy between the percentage of depletion and the amount of
metabolite quantified by UPLC-MS/MS can in most cases be
explained by the formation of additional metabolites. This is
especially the case for the MT66-mediated metabolism of
BUS where the detected 5-OH-BUS (MB4) is only detected
as a minor metabolite by IT-TOF. Trends of the metabolic
activities and diversities measured by LCQ during the single
substrate screening experiment and by IT-TOF during the
cocktail screen correspond well. Mutants that displayed good
activity during the single substrate screen also displayed good
activity during the cocktail screen and metabolic profiles were
very similar. This again demonstrates that co-administration
of multiple drugs in a single incubation has no major effects
on the metabolic activity and diversity of the tested mutants.
The largest peak in Fig. 4a appears to be the N-
demethylated product MM (MD6) (and parallel with it its
m/z+1 isotope) of DEX. When plotting the mass traces of
m/z 258 (data not shown), it was found that the majority of
the mutants produced the N-demethylated product MM
(MD6) as the major product (see also ESM, Fig S3 and
Table S5). Very small amounts of theO-demethylated product
dextrorphan were also seen in this plot (at 11.55 min). These
were formed by a selection of mutants (MT34, MT35, MT36,
MT37, MT38 and MT42) which contained mutations at
active-site residues S72, A74 or L437. However, also for these
mutants, MM was the major product.
By using biplots, either directly or after removing the main
peaks, the prominent metabolites of the various substrates can
be retrieved (satisfying goal 1 and 5 when combined with
mass traces or plots of the selected peaks for all mutants).
Most of the times, the mutants that lie in the direction of such
a peak produce high amounts of that specific metabolite. The
procedure of removing the main peaks from the data,
reconstructing and analysing the biplot, can be repeated, there-
by retrieving also less prominent metabolites. Another ap-
proach is the ROBPCA-based outlier detection procedure.
When applied on the data, it appeared that sample 32, which
corresponds withMT66, was an outlying sample (see Fig. 5a).
In Fig. 5b, the variables are plotted which are responsible for
this outlying behaviour. The peaks as variable 202–204 and
206 appear to be peaks with a m/z value of 288 (the adjacent
small peaks are their M+1 isotopes), being four hydroxylated
DEXmetabolites which almost uniquely and in large amounts
are produced by MT66 which displayed the highest activity
towards DEX (see Fig. 5c).
UPLC overall has shown that a cocktail approach can be
used to screen CYP BM3 mutants for metabolic activity and
diversity. Different approaches have been used to assess the
activities of the mutants. On the one hand, a UPLC-MS/MS-
based method was used that measured depletion of the parent
drugs and additionally monitored formation of at least one
probe metabolite for each drug. This method made use of very
short gradients (<5 min) and can be used to screen large
amounts of samples in a relatively short time. The results of
the UPLC-MS/MS-based screening were used to calculate
substrate depletions for the tested drugs by the mutant library
which, in most cases, provided reliable information about the
activities of the mutants towards the tested drugs (except for
COU). Inclusion of at least one probe metabolite for each drug
makes the screening assay more reliable since it will make it
easier to identify false positives when it is known which me-
tabolite is expected to be formed. However, this is of course
not always possible, especially not when the purpose of the
screening is to identify novel mutants that can create chemical
diversity by forming novel metabolites. Additional qualitative
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analysis of selected samples by an information-rich analysis
method such as LC-MS/MS proved to be very valuable during
this study as it provided much needed information about the
metabolic profiles generated by the different mutants. The
results of the screening suggest that the majority of the CYPs
screened displayed a metabolic profile that is most similar to
CYP3A4 (see ESM for more details). The chemometrical
analysis facilitated an easy visualization and screening of the
Fig. 5 (A) ROBPCAplot of data set. Samples positioned in the upper left
quadrant are called orthogonal outliers. Also samples in the upper right
quadrant can be investigated; (B) a plot of the variables responsible for the
outlying behaviour of sample 32=MT66; the variable numbers in this
plot are linked to chromatographic peaks at specific m/z – RT
combinations; (C) a mass trace of m/z 288 showing the five
hydroxylated DEX metabolites MD1-MD5; the sample numbers
indicate the order of the samples in the data set. In the biplot in Fig. 4a,
they are linked to the mutant (MT) numbers, used in other figures and
tables
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resulting data and a quick retrieval of the metabolites of the
substrate cocktail. This appeared to be less laborious and time-
consuming than manual analysis of the data.
Conclusions
With the experimental setup chosen, significant differences in
the drug-metabolizing potential were encountered for the CYP
BM3 mutants tested and large differences in the biotransforma-
tion profiles generated were established. Therefore, it can be
concluded and proven based on the data presented that the pro-
posed analytical strategy is valid, and that we successfully de-
veloped a LC-MS/MS-based cocktail screening method for the
classification of CYP BM3 mutant libraries for metabolic activ-
ity in a quantitative assay method and diversity in a qualitative
assay method. By combining all data, the classification of the
mutants was made feasible using well-defined chemometrical
methods for the rapid and valuable mining of the data. Hence,
the classification is of crucial importance to select the proper
mutants to generate predesigned compound libraries rather than
screening all mutants for each sort of biotransformation. The
mutants described in this study could be useful as a starting point
for further site-directed or random mutagenesis, to further en-
hance metabolic efficiency and change substrate diversity and
regioselectivity. More research to rationalize the effects of the
introduced mutations would be very valuable in this process. In
the current study, the presented strategy was used to evaluate the
metabolic efficiency of a library of CYP BM3 mutants towards
in total six drugs. The analytical approach and designed exper-
iments described in this article will form the basis for future
research in screening for CYP BM3 mutants with improved
metabolic activity and diversity. This will aid to further improve
lead diversification in the drug discovery process and biosyn-
thesis of drug(like) metabolites.
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